Nanthealth LLC (NYSE:NH) shares were down 5.5% during mid-day trading on Thursday . The stock traded as low as $12.26 and last traded at $12.39, with a volume of 74,158 shares. The stock had previously closed at $13.11.

A number of analysts recently commented on NH shares. FBR & Co reaffirmed a “buy” rating on shares of Nanthealth in a research note on Thursday, August 18th. Jefferies Group started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating for the company. Canaccord Genuity started coverage on Nanthealth in a research note on Monday, June 27th. They issued a “buy” rating and a $17.00 price target for the company. First Analysis started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target for the company. Finally, Cowen and Company started coverage on Nanthealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 price target for the company. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Nanthealth presently has a consensus rating of “Buy” and a consensus target price of $18.00.

The company has a 50 day moving average price of $11.44 and a 200 day moving average price of $12.42. The firm’s market capitalization is $1.52 billion.

Nanthealth (NYSE:NH) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.26. The company had revenue of $31.50 million for the quarter, compared to analysts’ expectations of $23.55 million. The business’s quarterly revenue was up 166.9% on a year-over-year basis. On average, equities research analysts expect that Nanthealth LLC will post ($0.63) EPS for the current fiscal year.

In related news, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $10,000,004.00. Following the purchase, the insider now directly owns 15,000,000 shares of the company’s stock, valued at approximately $210,000,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick Soon-Shiong acquired 357,143 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were bought at an average price of $14.00 per share, with a total value of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.